| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00 |
| filingDate |
1995-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5a8748351005ad9017d3dfb5034dcae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb1f2242de94c9209e9528c207c352d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a812ce8fba8a70dcaeaecd49903caae3 |
| publicationDate |
1996-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H08208510-A |
| titleOfInvention |
Interferon composition |
| abstract |
(57) [Abstract] [Problem] To increase the bioavailability of interferon, To provide an improved formulation for non-parenteral administration of interferon thereby enhancing the therapeutic effect of interferon. SOLUTION: a) A therapeutically effective amount of interferon; b) Formula (1) (1) 1% by weight to 20% by weight of the compound represented by the formula (wherein n is 12 on average): and (2) 1% by weight of at least one pharmaceutically acceptable salt of caprylic acid or capric acid A pharmaceutical composition comprising 0% to 90% by weight of a compound of the formula (2) (wherein n is 6 or 8) in an amount of 20% by weight of the absorption enhancing system; |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9682054-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7745488-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8487001-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010053135-A |
| priorityDate |
1994-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |